BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
-2.92%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.45B
AUM Growth
+$2.45B
(-8.1%)
Cap. Flow
+$13.9M
Cap. Flow
% of AUM
0.57%
Top 10 Holdings %
Top 10 Hldgs %
48.53%
Holding
78
New
8
Increased
20
Reduced
11
Closed
4
Top Buys
| 1 |
Galapagos
GLPG
|
$58.9M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$49.4M |
| 3 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$33.7M |
| 4 |
Kymera Therapeutics
KYMR
|
$32.3M |
| 5 |
Tyra Biosciences
TYRA
|
$29.8M |
Top Sells
| 1 |
Merus
MRUS
|
$153M |
| 2 |
argenx
ARGX
|
$86.1M |
| 3 |
Relay Therapeutics
RLAY
|
$28M |
| 4 |
Forte Biosciences
FBRX
|
$19.9M |
| 5 |
Immunovant
IMVT
|
$13.5M |
Sector Composition
| 1 | Healthcare | 98.3% |
| 2 | Financials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GH Research
GHRS
$837M
| $205M | 7.98% | 9,275,158 +2 | +0% | +$44 |
|
|
2
Kymera Therapeutics
KYMR
$2.95B
| $187M | 7.29% | 3,180,658 +550,000 | +21% | +$32.3M |
|
3
Olema Pharmaceuticals
OLMA
$375M
| $184M | 7.16% | 6,661,503 | – | – |
|
4
Arcus Biosciences
RCUS
$1.13B
| $113M | 4.39% | 3,229,822 +432,000 | +15% | +$15.1M |
|
|
5
argenx
ARGX
$43.6B
| $111M | 4.31% | 366,204 -285,000 | -44% | -$86.1M |
|
6
Repare Therapeutics
RPTX
$71.7M
| $97.7M | 3.81% | 3,722,398 | – | – |
|
7
Xoma
XOMA
$392M
| $87.4M | 3.41% | 3,530,543 | – | – |
|
8
Protagonist Therapeutics
PTGX
$3.67B
| $69.1M | 2.7% | 3,901,759 +147,664 | +4% | +$2.62M |
|
9
Lexicon Pharmaceuticals
LXRX
$400M
| $69.1M | 2.69% | 14,360,000 +5,966,000 | +71% | +$28.7M |
|
10
Revolution Medicines
RVMD
$7.1B
| $68.4M | 2.67% | 2,485,049 | – | – |
|
|
11
Relay Therapeutics
RLAY
$619M
| $64.6M | 2.52% | 2,049,113 -889,089 | -30% | -$28M |
|
|
12
Galapagos
GLPG
$2.07B
| $58.9M | 2.3% | +1,119,733 | New | +$58.9M |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $58.2M | 2.27% | 11,407,182 +9,691,201 | +565% | +$49.4M |
|
14
4D Molecular Therapeutics
FDMT
$288M
| $54.1M | 2.11% | 2,005,862 | – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $47.5M | 1.85% | 2,486,429 | – | – |
|
16
AC Immune
ACIU
$205M
| $46.5M | 1.82% | 6,935,179 -1,610,000 | -19% | -$10.8M |
|
17
Verastem
VSTM
$569M
| $46.1M | 1.8% | 14,977,258 +3,691,000 | +33% | +$11.4M |
|
|
RAIN
18
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $44.2M | 1.73% | 2,957,807 +1,011,858 | +52% | +$15.1M |
|
|
WHWK
19
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $33.7M | 1.31% | +1,147,052 | New | +$33.7M |
|
20
Spero Therapeutics
SPRO
$116M
| $33.3M | 1.3% | 1,809,352 -328,626 | -15% | -$6.05M |
|
21
Kura Oncology
KURA
$686M
| $30.6M | 1.19% | 1,635,112 | – | – |
|
|
22
Tyra Biosciences
TYRA
$675M
| $29.8M | 1.16% | +1,694,933 | New | +$29.8M |
|
|
INFI
23
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $28.7M | 1.12% | 8,383,645 | – | – |
|
|
PVLA
24
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $27.5M | 1.07% | 5,328,239 | – | – |
|
25
Replimune Group
REPL
$422M
| $27.5M | 1.07% | 926,529 +7,601 | +0.8% | +$225K |
|